Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company reported a revenue of 1.228 billion yuan for Q1-Q3 2025, representing a year-on-year increase of 16.66%, and a net profit attributable to shareholders of 136 million yuan, up 15.21% year-on-year [2] - The company is focusing on a dual strategy of marketing and research and development to enhance product and brand strength, particularly emphasizing the core brand "Lengsuanling" [3] - The company has strategically reduced marketing expenditures, resulting in a stable net profit margin despite a decline in gross margin due to changes in product structure [4][5] - The company is well-positioned in the oral care market, particularly in the sensitive segment, and is actively expanding into high-end markets and oral healthcare, which is expected to create new growth opportunities [6] Financial Performance Summary - For Q1-Q3 2025, the company achieved a gross margin of 50.50%, a net profit margin of 11.06%, and a net cash flow from operating activities of 177 million yuan, reflecting a year-on-year increase of 10.48% [2][4] - The company’s revenue projections for 2025-2027 are adjusted to 1.791 billion, 2.073 billion, and 2.414 billion yuan respectively, with net profits of 189 million, 226 million, and 269 million yuan [6][8] - The earnings per share (EPS) for 2025-2027 are projected to be 1.10, 1.32, and 1.56 yuan, with corresponding price-to-earnings (PE) ratios of 36, 30, and 26 times [6][8]
登康口腔（001328）：Q3战略性控费，业绩维持稳增